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Summary: A questionnaire was circulated to European countries seeking information on the criteria used for 
acceptable performance in external quality assessment schemes. Responses were obtained from 21 countries. Fixed 
limits are used in 13 countries but the basis for these varies widely and includes clinical decision making, biological 
variation, views of experts, the state-of-the-art, and combinations of approaches. Variable limits based upon statisti­
cal analysis of the performance attained are used in 8 countries. The many advantages of harmonization in Europe 
have prompted the development of criteria based upon within- and between-subject biological variation for use in 
schemes which circulate single specimen challenges. Currently used criteria, which show much diversity, are com­
pared with these proposals, and the empirical nature of the majority of the former is demonstrated.
Introduction countries. On the one hand this is an advantage, because
This work was done by a Working Group which was k allows the EQAS t0 be adaPted t0 the sPeciaI Pre‘ 
formed in 1994, as consequence of various European vailinS s!tuation in each country- 0 n  the other hand il
EQAS-organizers’ meetings held under the umbrella creates difficulties with respect to the ongoing social and
of the CEC Standards, Measurements and Testing Pro- economic harmonization efforts within Europe and Pre-
gramme (formerly BCR). The aim of the Working vents the setting up of a uniform health care policy.
Group is to collaborate in the harmonization of results We stress that this paper is not related to the possible
in the field of laboratory medicine; it acts on a volun- role of EQAS for accreditation purposes. Rather, it
tary basis, in conjunction with three other Working asserts that the main objective of EQAS is to help
Groups coordinated by Dr. Adam Uldall, of Iierlev laboratories in the creation of quality and to promote
Hospital, Denmark. transferability of results among European countries.
At present, external quality assessment schemes (EQAS) The two principal aims of EQAS are to define target
exist in the field of laboratory medicine in many coun- values, and to define the limits for acceptance. The
tries. Most of these are intended to assist individual target values should be assigned from reference mcth-
laboratories to continuously monitor their performance, ods, but as only a few schemes follow these principles,
and to compare it with that of other laboratories, target values are derived from the statistics of each sur-
whereas others may be intended primarily for accredita- vey (overall or method-group mean). Although the rele-
tion/licensing purposes. Additionally, EQAS may moni- vant differences among countries are pointed out in this
tor the quality of commercial analytical systems, rea- paper, they do not constitute the basis of this work. The
gents and test kits, and they help manufacturers to reason for this decision is that to promote changes on
achieve a better harmonization of the results from these this subject implies that the design of programmes must
different analytical techniques. Owing to these different be reviewed (management field), and the aim of the
aims and its different stages of development, the design Working Group is primarily intended to stimulate
of EQAS varies to a great extent in individual European thought (the inherent educational role of current EQAS),
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In particular, it has been realized in the recent years that 
a major obstacle to the harmonization of European 
EQAS is the different acceptance of limits used in indi­
vidual countries. These limits are the interval within 
which the results of an individual laboratory must lie to 
be considered as acceptable. In consequence, the Work­
ing Group tried to develop a concept for deriving accep­
tance limits for EQAS which should be generally appli­
cable all over Europe. Before doing this, the group felt 
it of great importance to have a picture of currently used 
limits and to understand the reasons underlying their 
generation. For this purpose, a questionnaire was sent to 
European EQAS organizers, seeking information on the 
criteria for setting limits and the actual numbers used 
for general biochemical quantities. Data from 21 coun­
tries have been received and are presented here. In addi­
tion, the Working Group outlines a concept for deriving 
EQAS acceptance limits from biological variation, 
which is intended for use as a common European work­
ing basis for currently conducted schemes.
Results and Discussion
The information provided reveals two main types of cri­
terion for defining EQA limits:
i) criteria based on biological variation, opinions of ex­
perts, “fixed” state-of-the-art, or combinations of these, 
leading to “fixed limits”;
ii) statistical criteria applied to the outcome of each sur­
vey, leading to “variable limits” (real state-of-the-art 
limits) (tab. 1).
i) Fixed limits are used in 13 out of the 21 countries 
which responded to the questionnaire. But, as addressed
Tab. 1 Criteria for defining limits in EQAS 
Abbreviations:
CVbi = within-subject coefficient of variation; CVwiab = within- 
laboratory coefficient of variation; P95 = 95th percentile; clin = 
clinicians; CCV = chosen coefficient of variation
Country Fixed limits Country Variable
limits
Denmark 3(1/2 CVbi) Italy
(Lombardia)
P95
Netherlands 3 (1/2 CVbi) Spain P95
Belgium Biology France P95>
Germany 3 (CVwiab) Portugal P95> i?99
Czech Republic 3 (CVwlab) Iceland Murex
Luxembourg 3 (CVwlab) Greece —
Finland Experts, P95 Russia —
(labquality)
Norway Labquality Sweden —
Switzerland Clin, analysts
Croatia 2 (CVwlflb)
Lithuania —
Ireland CCV
United Kingdom CCV
above, the criteria for deriving them vary to a great ex­
tent:
-  Denmark (DK) recommends three times half the 
within-subject biological variation (sL), using the desir­
able analytical standard deviation goal (sa) for routine 
methods, which is sa <  0.5 s\ (1, 2). But, being well 
aware that many routine methods currently do not meet 
this desirable goal for analytical standard deviation (e. g. 
methods for sodium, chloride, calcium, protein), the re­
sulting EQA limits are meant as targets to be reached in 
the future rather than for judgement of current perfor­
mance.
-  The Netherlands (NL) use principally the same ap­
proach as described above for Denmark. As in Denmark, 
some of the limits are used as an aim to be strictly ap­
plied only in the future. On the other hand, lower limits 
are used for some quantities when the respective meth­
ods perform much better than required by strict adher­
ence to desirable analytical goals (e. g. lactate dehydro­
genase, aspartate aminotransferase and alanine amino­
transferase). A peculiarity of this EQA scheme is that, in 
contrast to the generalized approach of single specimen 
challenges, they conduct a multispecimen testing 
scheme with the establishment of the laboratory mean 
and standard deviation, computed from eight results ob­
tained in each time period. Thereafter, the statistically 
expected percentage (equal to the score of the partici­
pant) of results residing in the range of target ± three 
times the tabulated within-subject biological variation, 
is calculated (3).
-  Belgium (BE) also uses limits based on biological 
variation, while respecting desirable analytical goals ac­
cording to the combined allowable bias and standard de­
viation limits as proposed by Fraser & Hyltoft (4). How­
ever, for quantities where current analytical performance 
does not meet these goals, the desirable EQA limits are 
substituted by practical ones, derived from the state-of- 
the-art, as proposed in the document produced by a 
working group of EGE-Lab (5).
— Germany (DE) uses limits which are three times the 
maximum within-laboratory standard deviation (s), 
which themselves were derived from the respective ref­
erence intervals (6); but, additionally, take into account 
the analytical state-of-the-art at the time when the Ger­
man guidelines became mandatory (7). Unique in the 
German scheme is the use of reference method target 
values for many quantities which, in turn, sometimes 
necessitates higher EQA limits than in other countries.
— The Czech Republic and Luxembourg have adopted 
the German system.
— Finland (FI) (and also Norway which participates in 
the Finnish scheme) and Switzerland (CH) use accept­
able limits set by experts, which take account of the
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clinical decision, the biological variation and the 95% Spain (ES), Italy (IT) (Lombardia), France (FR) and
in limit analytical state-of-the-art. (It should be noted Portugal (PT) judge all results acceptable which fall 
here that since January 1995 Denmark, Norway, Iceland within the 95% or 99% interval (depending on the quan-
and Finland have been using mutual limits).
Croatia (CR) reported the use of limits which were
tity) around the mean.
Iceland (IS) participates in a commercial scheme
twice the maximum within-laboratory CV, without ex- (Murex Diagnostics) which uses statistical acceptance
plaining how the respective CV data were derived. criteria similar to those described above, but the actual
-  Lithuania reported the use of fixed limits, but again were not reported, 
without explaining the underlying concept. _  £ q ^  scheme in Russia
-  The United Kingdom (GB) uses average CV values without using acceptance limits.
informative
based on historical observed data from the scheme, Sweden started an EQA scheme as recently as 1992
established around 20 years ago (CCV) (8), for partici- and has not t formulated acceptance limits; the same
pant assessment.
-  Ireland (IE) has adopted the GB system, but classifies 
participants as poor only when their results are “far 
away” from those of the majority.
is true for Greece.
The limits reported by the different countries are pre­
sented in tables 2 —4 (countiy grouping is identical to 
that in tab. 1). It should be noted here that most schemes
ii) eight countries base their limits for EQA on the actual work with single analysis of specimens and participant 
outcome of each survey. Therefore, the values given in assessment in each survey (except the Netherlands and 
tables 2—4 represent an average of results from recently the United Kingdom, which use cumulative survey data
conducted surveys. for performance assessment). As mentioned above, no
Tab. 2 Currently used European EQA limits (given in % deviation from the target)
Na Cl Ca Mg Albumin Protein Glucose K Creatinine
Denmark 0.9 2.1 2.7 3.5 4.2 4.2 6.6 8.2 6.6
Netherlands 0.9 2.1 2.7 3.3 4.2 4.2 10.0 7.2 6.6
Belgium 2.0 3.0 4.5 9.5 6.2 5.5 14.0 8.0 8.0
Germany0 6.0 6.0 10.0 12.0 18.0 9.0 15.0 8.0 18.0
Finland“ 3.0 3.0 3.0 5.0 5.0 5.0 5.0 3. 5.0
Switzerland 2.0 3.0 4,0 4.0 6.0 3.0 7.0 3.0 15.0
Croatia 3.0 4.0 5.0 — — 8.0 5.0 5.0 10.0
Lithuania 3.0 3.0 2.0 — 3.0 3.0 5.0 2.0 5.0
United Kingdom 1.6 2.2 4.0 10.0 7.5 3.9 7.7 2.9 8.9
Spain 6.6 10.0 10.0 — 14.0 9.2 9.8 7.4 14.0
Italy 2.0 4.0 5.5 — 4,0 4.0 6.0 3.0 8.8
France 3.5 4.0 4.6 12.0 10.0 10.0 11.0 6.8 11.0
Portugal 2.5 6.0 7.0 — — 5.0 6.0 5.0 12.0
same limits for Czcch Republic and Luxembourg 
l) same limits for Norway
Tab. 3 Currently used European EQA limits (given in % deviation from the target)
Cholesterol Pi Lithium Lactate
dehydrogenase
Urate Alkaline
phosphatase
Amylase
Denmark 8.1 12.0 — 12.0 13.0 10.0 11.0
Netherlands 8.1 — 5.0 3.0 10.0 8.0 10.0
Belgium 8.4 14.0 10.0 15.0 15.0 10.0 17,0
Germany1 18.0 15.0 12.0 21.0 18.0 21.0 21.0
Finland 5.0 5.0 5.0 10.0 5.0 10.0 10.0
Switzerland 3.0 10.0 6.0 15.0 10.0 15.0 20.0
Croatia 10.0 10.0 — 20.0 10.0 20.0
Lithuania 7.0 5.0 — 7.0 7.0 7.0 10.0
United Kingdom 7.6 7.8 11.0 13.0 7.7 15.0 11.0
Spain 9.8 12.0 22.0 17.0 15.0 22.0 56,0
Italy 5.5 9.5 — 10.0 8,0 18.0 **—
France 16.5 — 10.0 20.0 16.0 20.0 25.0
Portugal 5.0 8.0 — 16.0 9.0 29.0 —
a same limits for Czcch Republic and Luxembourg 
b same limits for Norway
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cal variation.
data are shown in tables 2—4 for the Czech Republic, dium they vary between 0.9% in Denmark and 6.6% in
Luxembourg, Norway and Ireland because they have Spain (tab. 2), for cholesterol from 3% in Switzerland
adopted values from other countries. In addition, Russia, to 18% in Germany (tab. 2), and for urea from 5% in
Sweden, Greece and Iceland are not represented, either Finland to 24% in Germany (tab. 4). The same wide
because acceptance limits are not used in those coun- disagreement may be seen in figure 2, where data have
tries, or because they were not reported» Further, quanti- been grouped according to the type of limits used: fixed
ties have been arranged according to increasing biologi- limits on the left and variable limits on the right.
This is not surprising because the different EQA
This principle was also used for creating figure 1> which schemes have different aims and are conducted under
is intended to give a rapid overview of the limits without different constraints. Countries basing their limits on
indicating the countries applying them. In figure 1 also, biology (e. g. Denmark and The Netherlands) have nar-
the values derived from the concept of the Working row limits for analytes with a low biological variation
and wide limits for analytes with high biological varia-
As can be seen from figure 1 and tables 2—4, the cur- tion. But the former in particular are primarily intended
rently used European EQA limits show relatively high as goals to be reached in the future, In practice, they are
variation for nearly all quantities. For example, for so- often widened for quantities with a narrow biological
Group (see below) are included, using the symbol “a”
Tab, 4 Currently used European EQA limits (given in % deviation from the target)
Urea Aspartate
amino­
transferase
Bilirubin y-Glutamyl-
transferase
Triacyl-
glycerol
Alanine
amino­
transferase
Fe Creatine
kinase
Denmark 19.0 22.0 34.0 22.0 34.0 41.0 48.0 62.0
Netherlands 19.0 7.0 33.0 18.0 33.0 10.0 30.0 63.0
Belgium 16.0 16,0 24.0 15.0 20.0 20.0 — 20.0
Germany 24.0 21.0 24.0 21.0 21.0 21.0 21.0 24.0
Finland5 5.0 10.0 10,0 10.0 10.0 10.0 10.0 10.0
Switzerland 7.0 15.0 30,0 15.0 10.0 15.0 12.0 20.0
Croatia 7.0 20.0 10,0 20.0 10.0 20.0 10.0 20.0
Lithuania 7.0 7.0 — 10.0 7.0 7.0 5.0 7.0
United Kingdom 5.7 12.0 19.0 13.0 — 15.0 15.0 18.0
Spain 10.0 17.0 28.0 18.0 14.0 17.0 16.0 52.0
Italy 9.5 10.0 — 13.0 8.5 13.0 9.0 16.0
France 16.0 20.0 15,0 20.0 15.0 20.0 20.0 25.0
Portugal 6.0 12.0 13.0 11.0 7.0 11.0 7.0 14.0
a same limits for Czech Republic and Luxembourg 
b same limits for Norway
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Fig. 1 Current European EQA limits.
Analytes arranged in ascending biological variation.
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Fig. 2 Interlaboratory variation limits for cholesterol
variation, in order to reach realistic acceptance figures such as common standardization (including calibrators,
which can be presented to the participants (Belgium control materials with minimum matrix effect, etc) and
and The Netherlands). Germany, with a mixture of reliable target values may also be addressed in this
biology and state-of-the-art limits, as well as providing context, But these considerations are beyond the scope
a scheme acceptable by the health insurance system, of this work, 
has to use relatively large limits, except for quantities
where the current analytical performance is much bet' The co n cep t o f  the W ork ing  G roup
ter than required by biology (e. g, enzyme activity Considering the data received, we believe that there is a
assays). EQA limits set by experts (Finland and Swit- strong need for harmonization of EQA limits in Europe.
zerland) take account of current analytical perfor- But> it is c]ear that harmonized European EQA limits
mance, in turn leading to relatively wide limits for are on(y possible with a harmonized analytical design of
quantities with narrow biological variation like so- tjie schemes (e. g. single or multiple measurements, sin-
dium, albumin or calcium. On the other hand, they gie target or multiple targets, 95 or 99% confidence in­
show a tendency to set a general upper EQA limit terval).
which is 10% in the case of Finland. Interestingly, 
Lithuania follows the Finnish limits very closely, pos­
sibly because these two countries are geographically 
close. Croatia, did not reported the basis of its limits, 
and sets an upper limit of 20%.
Therefore, the Group first had to define the situation to 
which their concept should be applicable. Because most 
schemes use single measurements and certain cut-off 
values for judgement of performance, the Working 
Group restricted itself to this design. This does not mean
Among the countries using variable limits, reflecting the that the Working Group recommends this approach for
“rear1 state-of-the-art, Spain generally shows the highest the future. On the contrary, it recommends development
limits, while Italy mostly shows the lowest. This might of alternative EQA models (9), more appropriate for in-
be due to the different statistical levels applied for ac- structive purposes, but which are out of the scope of this
ceptance, the wide diversity of procedures used or the presentation. The model presented below, therefore, is
different types of laboratories participating (e.g. studies primarily intended as a realistic working basis for EQA
made in Spain revealed that in certain areas all laborato- schemes as they are conducted today. In any case, the
ries use the same procedures with a consequent general Working Group is convinced that a theoretical concept
agreement of results, and that the group of public based on biology should be the stalling point for deriv-
laboratories had less variation than the overall group; in ing EQA limits for eveiy situation. Moreover, EQA lim-
the case of Italy only one specific geographical area has its have to be built on quality specifications for routine
submitted data to our questionnaire), or the different methods. The Group therefore chose, as the principal
targets used (e. g. overall mean or group target). In addi- underlying concept for deriving EQA limits, the desir-
tion, also in this group, there seems to be a tendency able specifications for routine method bias and random
for setting upper limits (e.g. in France, 20—25% for error combined (5, 10), which are the sources of uncer-
enzymes). As pointed out above, the United Kingdom is tainty affecting a single analysis. Then, the desirable
unique because performance is judged from cumulated EQA limits (or desirable maximum deviation of a partic-
data, which mostly allows more narrow limits to be used ipant from the target = D%) can be expressed as fol-
than in the other countries in this group. Other issues lows:
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D <  K X 0.5 CVj +  0.25 (CV? + CV|)1/2
K = 1 .6 5  or 2.33 for 95 or 99% acceptance 
CVj =  average within-subject biological variation 
CVg = average between-subject biological variation
We preferred the use of coefficient of variation over 
standard deviation because nearly all EQA schemes use 
the former.
According to this formula, the percentage deviations of 
a single analysis derived from biology (99% confidence 
interval) for the quantities studied are shown in table 5. 
Figure 1 shows that quantities with low biological varia­
tion (sodium, chloride, calcium and albumin) have nar­
row acceptance limits. At present veiy few countries 
maintain interlaboratory vaiiation within these restricted 
intervals, but a general application of these limits would 
spur manufacturers to develop improved analytical pro­
cedures. However, we emphasize that other mechanisms
Tab, 5 Percentage deviations of a single analysis derived from 
biology (99% confidence interval)
Quantity Deviation
(%)
Na 0.90
Cl 2,13
Ca 2.80
Mg 4.16
Albumin 4.36
Total protein 4.8
Glucose 7,0
K 7.2
Creatinine 7,9
Cholesterol 10,4
Inorganic phosphate 12.4
Li 12,6
Lactate dehydrogenase 13.2
Urate 13,8
Alkaline phosphatase 14.3
Amylase 15.1
Urea 20.8
Aspartate aminotransferase 23.1
y-Glutamyl transferase 29.2
Bilirubin 36.2
Triacyl glycerol 42.6
Alanine aminotransferase 45.3
Fe 45,9
Creatine kinase 68.0
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